Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Chinese Medicine
Published in: Chinese Medicine 1/2022

Open Access 01-12-2022 | Helicobacter Pylori | Research

The tibetan medicine Zuozhu-Daxi can prevent Helicobacter pylori induced-gastric mucosa inflammation by inhibiting lipid metabolism

Authors: Yanyan Shi, Jing Ning, Kelsang Norbu, Xingzi Hou, Huiling Zheng, Hejun Zhang, Wei Yu, Feng Zhou, Yuan Li, Shigang Ding, Qingying Zhang

Published in: Chinese Medicine | Issue 1/2022

Login to get access

Abstract

Background

Tibetan medicine has been used in clinical practice for more than 3800 years. Zuozhu-Daxi (ZZDX), a classic traditional Tibetan medicine, has been proved to be effective in the treatment of digestive diseases, such as chronic gastritis, gastric ulcer, etc. Helicobacter pylori (H. pylori), one of the most common pathogenic microbes, is regarded as the most common cause of gastritis. Researching on the effects of ZZDX on H. pylori-induced gastric mucosa inflammation could provide more evidences on H. pylori treatment and promote the development of Tibetan medicine. This study aimed to explore whether ZZDX could rescue H. pylori-induced gastric mucosa inflammation and its mechanism.

Methods

Male C57BL/6 mice were infected with H. pylori, and orally treated with ZZDX to rescue gastric mucosa inflammation induced by H. pylori infection. Pathology of gastric mucosa inflammation was evaluated under microscopy by hematoxylin–eosin (HE) staining. The infection status of H. pylori was evaluated by immunohistochemical (IHC) staining. The reactive oxygen species (ROS) level in serum was evaluated using a detection kit. IL-1α, IL-6, and PGE2 expression levels in serum were measured using ELISA. IL-1α, IL-8, TNF-α, and NOD1 expression levels in gastric tissues were measured using real-time PCR. RNA sequencing and gene certification of interest were performed to explore the mechanisms in vivo and in vitro.

Results

The results showed that ZZDX could significantly inhibit H. pylori-induced gastric mucosa inflammation using HE staining. IL-1α, IL-6, and PGE2 expression levels in serum were significantly decreased after treatment with ZZDX. ZZDX treatment significantly decreased the mRNA expression of IL-8 induced by H. pylori infection in gastric tissues. Elovl4, Acot1 and Scd1 might be involved in the mechanisms of ZZDX treatment. However, the H. pylori infection status in the gastric mucosa was not reduced after ZZDX treatment.

Conclusions

ZZDX reversed gastric mucosal injury and alleviated gastric mucosa inflammation induced by H. pylori infection.
Literature
1.
Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.PubMedCrossRef
2.
3.
Navashenaq JG, Shabgah AG, Banach M, et al. The interaction of helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis. Semin Cancer Biol. 2021;86(Pt 3):951–9.PubMed
4.
Watari J, Chen N, Amenta PS, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol. 2014;20(18):5461–73.PubMedPubMedCentralCrossRef
5.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018;155(5):1372-1382.e1317.PubMedCrossRef
6.
Li Y, Li X, Tan Z. An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis. Helicobacter. 2021;26(3): e12799.PubMedCrossRef
7.
Liu WZ, Xie Y, Lu H, et al. Fifth Chinese national consensus report on the management of helicobacter pylori infection. Helicobacter. 2018;23(2): e12475.PubMedCrossRef
8.
Li L, Meng F, Zhu S, et al. Efficacy and safety of Wei Bi Mei, a Chinese herb compound, as an alternative to bismuth for eradication of helicobacter pylori. Evid Based Complement Alternat Med. 2018;2018:4320219.PubMedPubMedCentral
9.
Li RJ, Dai YY, Qin C, et al. Application of traditional Chinese medicine in treatment of Helicobacter pylori infection. World J Clin Cases. 2021;9(35):10781–91.PubMedPubMedCentralCrossRef
10.
Zuskin E, Lipozencić J, Pucarin-Cvetković J, et al. Ancient medicine–a review. Acta Dermatovenerol Croat. 2008;16(3):149–57.PubMed
11.
Hai J. Effect of western medicine triple combination combined with Tibetan medicine Zuozhu-Daxi pill on improving gastrointestinal function and serum CRP and IL-4 levels in the treatment of peptic ulcer. Chin J Ethnic Med. 2022;28(2):7–8.
12.
Hu W. Clinical observation on the treatment of digestive tract tumor vomiting after chemotherapy with Zuozhu-Daxi combined with Astragalus injection and Xiaobanxia pill. Jilin Medical J. 2011;32(8):1500–1.
13.
Baj J, Korona-Glowniak I, Forma A, et al. Mechanisms of the epithelial-mesenchymal transition and tumor microenvironment in helicobacter pylori-induced gastric cancer. Cells. 2020;9(4):1055.PubMedCentralCrossRef
14.
Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017;22(Suppl):1.
15.
Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting therapeutic strategies for H. pylori treatment in the context of antibiotic resistance focus on alternative and complementary therapies. Molecules. 2021;26(19):6078.PubMedPubMedCentralCrossRef
16.
Varghese R, Dalvi YB. Natural products as anticancer agents. Curr Drug Targets. 2021;22(11):1272–87.PubMedCrossRef
17.
Winand L, Sester A, Nett M. Bioengineering of anti-inflammatory natural products. ChemMedChem. 2021;16(5):767–76.PubMedCrossRef
18.
El-Tantawy WH. Natural products for the management of hyperuricaemia and gout: a review. Arch Physiol Biochem. 2021;127(1):61–72.PubMedCrossRef
19.
Zhang S, Li L, Chen W, Xu S, Feng X, Zhang L. Natural products: the role and mechanism in low-density lipoprotein oxidation and atherosclerosis. Phytother Res. 2021;35(6):2945–67.PubMedCrossRef
20.
Boozari M, Hosseinzadeh H. Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies. Phytother Res. 2021;35(2):864–76.PubMedCrossRef
21.
Sadeer NB, Mahomoodally MF. Antibiotic potentiation of natural products: a promising target to fight pathogenic bacteria. Curr Drug Targets. 2021;22(5):555–72.PubMedCrossRef
22.
Yuan S, Gopal JV, Ren S, Chen L, Liu L, Gao Z. Anticancer fungal natural products: mechanisms of action and biosynthesis. Eur J Med Chem. 2020;202: 112502.PubMedCrossRef
23.
Wang H. Talk shallowly that on the clinical application of Tibetan medicine Zuozhu Daxi. Chin J Ethnomed and Ethnopharm. 2014;23:4–5.
24.
Shen F, Li X, Qi D, Jiang H, Guo Z, Chen P. Relationship between the genotypes of Helicobacter pylori in fection and gastroin testinal diseases. Chin J Nosocomiology. 2022;32(3):417–21.
25.
Bertheloot D, Latz E. HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol. 2017;14(1):43–64.PubMedCrossRef
26.
Zeng B, Chen C, Yi Q, et al. N-terminal region of Helicobacter pylori CagA induces IL-8 production in gastric epithelial cells via the β1 integrin receptor. J Med Microbiol. 2020;69(3):457–64.PubMedCrossRef
27.
Suganuma M, Watanabe T, Sueoka E, Lim IK, Fujiki H. Role of TNF-α-inducing protein secreted by helicobacter pylori as a tumor promoter in gastric cancer and emerging preventive strategies. Toxins. 2021;13(3):181.PubMedPubMedCentralCrossRef
28.
Suarez G, Romero-Gallo J, Piazuelo MB, et al. Nod1 imprints inflammatory and carcinogenic responses toward the gastric pathogen helicobacter pylori. Cancer Res. 2019;79(7):1600–11.PubMedPubMedCentralCrossRef
29.
Figueiredo CA, Marques CR, Costa Rdos S, da Silva HB, Alcantara-Neves NM. Cytokines, cytokine gene polymorphisms and Helicobacter pylori infection: friend or foe? World J Gastroenterol. 2014;20(18):5235–43.PubMedPubMedCentralCrossRef
30.
Chen Y, Wang X, Yu Y, et al. Serum exosomes of chronic gastritis patients infected with Helicobacter pylori mediate IL-1α expression via IL-6 trans-signalling in gastric epithelial cells. Clin Exp Immunol. 2018;194(3):339–49.PubMedPubMedCentralCrossRef
31.
Cao D, Jiang J, Tsukamoto T, et al. Canolol inhibits gastric tumors initiation and progression through COX-2/PGE2 pathway in K19–C2mE transgenic mice. PLoS ONE. 2015;10(3): e0120938.PubMedPubMedCentralCrossRef
32.
Gehrmann W, Würdemann W, Plötz T, Jörns A, Lenzen S, Elsner M. Antagonism between saturated and unsaturated fatty acids in ROS mediated lipotoxicity in rat insulin-producing cells. Cell Physiol Biochem. 2015;36(3):852–65.PubMedCrossRef
33.
Trommer S, Leimert A, Bucher M, Schumann J. Polyunsaturated fatty acids induce ROS synthesis in microvascular endothelial cells. Adv Exp Med Biol. 2018;1072:393–7.PubMedCrossRef
34.
Sun P, Zhou Q, Monroig Ó, et al. Cloning and functional characterization of an elovl4-like gene involved in the biosynthesis of long-chain polyunsaturated fatty acids in the swimming crab Portunus trituberculatus. Comp Biochem Physiol B Biochem Mol Biol. 2020;242: 110408.PubMedCrossRef
35.
Duan S, Zhang M, Li J, et al. Uterine metabolic disorder induced by silica nanoparticles: biodistribution and bioactivity revealed by labeling with FITC. J Nanobiotechnology. 2021;19(1):62.PubMedPubMedCentralCrossRef
36.
Li Z, Lu S, Cui K, et al. Fatty acid biosynthesis and transcriptional regulation of Stearoyl-CoA Desaturase 1 (SCD1) in buffalo milk. BMC Genet. 2020;21(1):23.PubMedPubMedCentralCrossRef
37.
Vasireddy V, Sharon M, Salem N Jr, Ayyagari R. Role of ELOVL4 in fatty acid metabolism. Adv Exp Med Biol. 2008;613:283–90.PubMedCrossRef
38.
Yang Y, Chen Z, Zhou L, et al. In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer. Transl Cancer Res. 2022;11(7):1977–93.PubMedPubMedCentralCrossRef
39.
Wang F, Wu J, Qiu Z, et al. ACOT1 expression is associated with poor prognosis in gastric adenocarcinoma. Hum Pathol. 2018;77:35–44.PubMedCrossRef
40.
Raeisi M, Hassanbeigi L, Khalili F, Kharrati-Shishavan H, Yousefi M, Mehdizadeh A. Stearoyl-CoA desaturase 1 as a therapeutic target for cancer: a focus on hepatocellular carcinoma. Mol Biol Rep. 2022;49(9):8871–82.PubMedCrossRef
41.
Wang C, Shi M, Ji J, et al. Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging. 2020;12(15):15374–91.PubMedPubMedCentralCrossRef
42.
Huang F, Ren W, Yang G. Clinical observation on therapeutic efficiency of tibean medicine used in treating atrophic gastritis. Chin J of Ethnic Med. 2000;6(1):10–2.
43.
Yu G, Tan Y. Clinical observation of combined treatment of Helicobacter pylori positive peptic ulcer with Zuozhu-Daxi. Chin J Adv Med Educ. 2012;35(z2):61–2.
44.
Hu M, Zhou H, Wang M, Chen C, Du Y. Recent development of study on mongolian medicine gypsum fibrosum. J Med Pharm of Chin Mnorities. 2014;20(9):34–6.
45.
Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic acid treatment restores gut microbiota and alleviates liver inflammation in non-alcoholic steatohepatitic mouse model. Front Pharmacol. 2021;12: 788558.PubMedPubMedCentralCrossRef
46.
Chen X, Mellon RD, Yang L, Dong H, Oppenheim JJ, Howard OM. Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants. Biochem Pharmacol. 2002;63(3):533–41.PubMedCrossRef
47.
Yu S, Zhao G, Han F, et al. Muscone relieves inflammatory pain by inhibiting microglial activation-mediated inflammatory response via abrogation of the NOX4/JAK2-STAT3 pathway and NLRP3 inflammasome. Int Immunopharmacol. 2020;82: 106355.PubMedCrossRef
48.
Chun J, Choi RJ, Khan S, et al. Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells. Int Immunopharmacol. 2012;14(4):375–83.PubMedCrossRef
49.
Luo M, Li C, Lin L, Wang Z, Guo W. Research progress on tibetan medicinal herb ponkar. Chin J Exp Tradit Med Formulae. 2012;18(12):298–302.
50.
Du Y, Wang X, Yang M. Advances in pharmacological activities of the medicinal plants of genus Veronica. Chin Med J Res Prac. 2013;27(06):77–80.
51.
Cai L, Wei Z, Zhao X, Li Y, Li X, Jiang X. Gallic acid mitigates LPS-induced inflammatory response via suppressing NF-κB signalling pathway in IPEC-J2 cells. J Anim Physiol Anim Nutr (Berl). 2022;106(5):1000–8.CrossRef
52.
Schütz K, Carle R, Schieber A. Taraxacum–a review on its phytochemical and pharmacological profile. J Ethnopharmacol. 2006;107(3):313–23.PubMedCrossRef
53.
Shetty NP, Prabhakaran M, Srivastava AK. Pleiotropic nature of curcumin in targeting multiple apoptotic-mediated factors and related strategies to treat gastric cancer: a review. Phytother Res. 2021;35(10):5397–416.PubMedCrossRef
54.
Alaribe CS, Esposito T, Sansone F, et al. Nigerian propolis: chemical composition, antioxidant activity and alpha-amylase and alpha-glucosidase inhibition. Nat Prod Res. 2021;35(18):3095–9.PubMedCrossRef
55.
Korona-Glowniak I, Glowniak-Lipa A, Ludwiczuk A, Baj T, Malm A. The in vitro activity of essential oils against helicobacter pylori growth and urease activity. Molecules. 2020;25(3):586.PubMedCentralCrossRef
56.
Ullah H, Di Minno A, Santarcangelo C, et al. Vegetable extracts and nutrients useful in the recovery from helicobacter pylori infection: a systematic review on clinical trials. Molecules. 2021;26(8):2272.PubMedPubMedCentralCrossRef
57.
Wang LS, Echeveste CE, Yu J, et al. Can natural products suppress resistant helicobacter pylori to fight against gastric diseases in humans. eFood. 2020;1(1):53–60.PubMedPubMedCentralCrossRef
58.
Roszczenko-Jasinska P, Wojtys MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol. 2020;104(23):9891–905.PubMedPubMedCentralCrossRef
59.
Lin J, Huang WW. A systematic review of treating Helicobacter pylori infection with traditional Chinese medicine. World J Gastroenterol. 2009;15(37):4715–9.PubMedPubMedCentralCrossRef
60.
Hu Q, Peng Z, Li L, et al. The efficacy of berberine-containing quadruple therapy on helicobacter pylori eradication in china: a systematic review and meta-analysis of randomized clinical trials. Front Pharmacol. 2019;10:1694.PubMedCrossRef
Metadata
Title
The tibetan medicine Zuozhu-Daxi can prevent Helicobacter pylori induced-gastric mucosa inflammation by inhibiting lipid metabolism
Authors
Yanyan Shi
Jing Ning
Kelsang Norbu
Xingzi Hou
Huiling Zheng
Hejun Zhang
Wei Yu
Feng Zhou
Yuan Li
Shigang Ding
Qingying Zhang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Chinese Medicine / Issue 1/2022
Electronic ISSN: 1749-8546
DOI
https://doi.org/10.1186/s13020-022-00682-9

Other articles of this Issue 1/2022

Chinese Medicine 1/2022 Go to the issue

Research

Downregulation of lncRNA Miat contributes to the protective effect of electroacupuncture against myocardial fibrosis

Research

Effects of acupuncture at acupoints with lower versus higher pain threshold for knee osteoarthritis: a multicenter randomized controlled trial

Research

Predicting for anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of Lianhua Qingwen Capsules in treating COVID-19

Research

Understanding the tonifying and the detoxifying properties of Chinese medicines from their impacts on gut microbiota and host metabolism: a case study with four medicinal herbs in experimental colitis rat model

Review

The application of mass spectrometry imaging in traditional Chinese medicine: a review

Research

Investigating the mechanism of Xian-ling-lian-xia-fang for inhibiting vasculogenic mimicry in triple negative breast cancer via blocking VEGF/MMPs pathway